Australian Pharmaceutical Industries Ltd
ASX:API
Relative Value
There is not enough data to reliably calculate the relative value of API.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
API Competitors Multiples
Australian Pharmaceutical Industries Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Australian Pharmaceutical Industries Ltd
ASX:API
|
753.8m AUD | 0.2 | 547.4 | 41.1 | 41.1 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
117.1B USD | 0.3 | 29.1 | 20.4 | 23 | |
| US |
|
Cencora Inc
NYSE:COR
|
69.7B USD | 0.2 | 44.8 | 15.1 | 19.4 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
68.2B USD | 0.2 | 44.4 | 15 | 19.3 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
53.9B USD | 0.2 | 32.4 | 15.6 | 20.2 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
36B AUD | 6 | 67.9 | 51.2 | 51.2 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
64.8B CNY | 1.5 | 17.5 | 13.5 | 13.5 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
64.1B CNY | 0.2 | 11.4 | 15.3 | 15.3 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.3B USD | 0.7 | 24.1 | 11.5 | 16.1 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
65.8B HKD | 0.1 | 8.6 | 1.6 | 2 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 5.9 | 89.6 | 59.9 | 61.9 |